

ATTORNEY DOCKET NO.: 0492611-0375(MIT 8802)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kamm, et al. Examiner:
Serial No: 09/815,528 Art Unit:
Filing Date: March 23, 2001
Title: METHOD AND APPARATUS FOR STIMULATING ANGIOGENESIS AND
WOUND HEALING BY USE OF EXTERNAL COMPRESSION

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

1. Form PTO-1449;
2. Information Disclosure Statement; and
3. Cited Art


If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,


C. Hunter Baker, M.D., Ph.D.
Reg. No. 46,533

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
Dated: May 10, 2001
3269021

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Trademarks, 2900 Crystal Drive, Arlington, VA 22202-3512 for Patents, on 5-10-01 Washington, DC 20231



JUN. 25. 2004 6:59PM

CHOATE HALL & STEWART 6172484000

NO. 686 P. 62

MIT

DC2

DATE MAILED VIA U. S. FIRST CLASS MAIL: MAY 10, 2001

Applicant: Kamm, et al.

Examiner:

Serial No: 09/815,528

Art Unit:

Filing Date: March 23, 2001

Atty. Docket No.:0492611-0375/MIT 8802

Title: METHOD AND APPARATUS FOR STIMULATING ANGIOGENESIS AND
WOUND HEALING BY USE OF EXTERNAL COMPRESSION

The U. S. Patent and Trademark Office stamping sets forth the receipt date
(or both the receipt date and Serial Number) of a patent application as
identified above.

1. Form PTO-1449;
2. Information Disclosure Statement;
3. Cited Art;
4. Return-receipt postcard.

Atty: CHB

3269287



OFFICIAL

ATTORNEY'S DOCKET NUMBER: 0492611-0375 (MIT 8802) RECEIVED
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
CENTRAL FAX CENTER JUN 25 2004

Applicant: Kamm, et al. Examiner:
Serial No.: 09/815,528 Art Unit:
Filed: March 23, 2001
For: METHOD AND APPARATUS FOR STIMULATING ANGIOGENESIS AND
WOUND HEALING BY USE OF EXTERNAL COMPRESSION

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

(Select A, B, C or D below)

A. This Information Disclosure Statement has been filed:

1. within three months of the filing date of the above identified U.S. Patent application other than a continued prosecution application under § 1.53(d);
2. within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International application;
3. before the mailing date of the first Office Action on the merits in the above-identified application; or
4. before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

No fee or certification is required.

B. This Information Disclosure Statement has been filed more than three months after the filing date of the present application and after the mailing date of the first Office Action, but before the mailing date of any of a final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application, and:

(check 1 or 2 below)

1. The fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed, OR
2. The Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that

(check a or b below)

- a. each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- b. no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.

C. This Information Disclosure Statement has been filed after the mailing date of either a Final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311 and on or before payment of the Issue Fee.

1. The Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that:

- a. each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- b. no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a

counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement; AND

2. The Petition Fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.
- D. [] This Information Disclosure Statement does not comply with any of the provisions set forth above, or is being submitted after the payment of the issue fee; however, Applicants respectfully request that the Statement be placed in the above-referenced file.

PART II - 37 CFR § 1.98 Content of Information Disclosure Statement:

- [] A. Applicants hereby make of record in the above-identified application all patents, publications, applications or other information submitted for consideration by the Office listed on the attached form PTO-1449 (modified). The order of presentation of the patents, publications, applications or other information should not be construed as an indication of the importance. Applicants have provided a legible copy of:
- each U.S. patent application publication;
 - each U.S. foreign patent;
 - each publication or that portion which caused it to be listed;
 - each pending U.S. application (including the application specification including the claims and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion); and
 - other information or that portion which caused it to be listed.

For each patent, publication, or other information listed that is not in the English language, the following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

Alternatively, if a written English-language translation of a non-English-language document, or portion thereof, if within the possession, or control of, or is readily available to any individual designated in § 1.56(c), a copy of the translation is provided herein as identified:

[] B. The Applicants hereby make the following additional information of record in the above-identified application:

PART IV: Remarks

A copy of each of the above-identified U.S. and foreign patent(s), publication(s), application(s) or other information submitted is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s), publication(s), application(s), or other information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more material information may not exist.

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited materials. An early and favorable action is hereby requested.

Respectfully submitted,



C. Hunter Baker, M.D., Ph.D.
Reg. No. 46,533

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
Date: May 9, 2001
3268886

I hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail in an envelope addressed to: Assistant
Commissioner For Patents, Washington, D.C. 20231
on 5-10-01


Form PTO-1449
(REV. 8-83)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket:
0492611-0375In re Application No.
09/815,528**INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

Applicant: Kamm, et al.

Filing Date:
March 23, 2001

Group:

U.S. PATENT DOCUMENTS

| Examiner's Initials | U.S. Patent No. | Applicant | Issue Date | Class | Subclass |
|---------------------|-----------------|----------------------|--------------------|-------|----------|
| | 3,707,960 | Freed | January 2, 1973 | 128 | 2.06 |
| | 3,783,859 | Sauer, et al. | January 8, 1974 | 128 | 24 |
| | 4,527,549 | Gabbay | July 9, 1985 | 128 | 1 |
| | 4,552,127 | Schiff | November 12, 1985 | 128 | 1 |
| | 4,692,148 | Kantrowitz, et al. | September 8, 1987 | 604 | 96 |
| | 4,966,849 | Vallee, et al. | October 30, 1990 | 435 | 199 |
| | 5,218,954 | van Bemmelen | June 15, 1993 | 128 | 24 |
| | 5,407,418 | Szpur | April 18, 1995 | 601 | 104 |
| | 5,486,457 | Butler, et al. | January 23, 1996 | 435 | 7.2 |
| | 5,496,262 | Johnson, Jr., et al. | March 5, 1996 | 601 | 152 |
| | 5,554,103 | Zheng, et al. | September 10, 1996 | 601 | 152 |
| | 5,997,540 | Zheng, et al. | December 7, 1999 | 606 | 64 |
| | 6,076,013 | Brennan, et al. | June 13, 2000 | 607 | 2 |
| | 6,078,235 | Schebitz, et al. | June 20, 2000 | 335 | 220 |

U.S. PATENT APPLICATIONS

| Examiner's Initials: | Serial Number: | Applicant: | Filing Date: | Group: | Art Unit: |
|----------------------|----------------|------------|--------------|--------|-----------|
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Document No. | Country | Date | Translation | |
|---------------------|--------------|---------|-----------------|-------------|----|
| | | | | Yes | No |
| | WO 00/40740 | PCT | 13 July 2000 | | |
| | WO 95/01770 | PCT | 19 January 1995 | | |

OTHER DOCUMENTS

| | |
|---------------------|--|
| Examiner's Initials | Citation (Including Author, Title, Date, Pertinent Pages, Etc.) |
| | Amsterdam, et al., "Clinical Assessment of External Pressure Circulatory Assistance in Acute Myocardial Infarction", <i>Am. J. Cardiol.</i> , 45: 349, 1990. |

JUN. 25. 2004 6:59PM

CHOATE HALL & STEWART 6172484000

NO. 686 P. 60

Form PTO-1449
(REV. 8-83)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket:
0492611-0375In re Application No.
09/815,528FORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant: Kamm, et al.

Filing Date:
March 23, 2001

Group:

| | |
|--|--|
| | Applebaum, et al., "Sequential External Counterpulsation Increase Cerebral and Renal Blood Flow", <i>American Heart Journal</i> , 133(6): 611-615, 1997. |
| | Arora, et al., "The Multicenter Study of Enhanced External Counterpulsation (MUST-EECP): Effect of EECP on Exercise-Induced Myocardial Ischemia and Anginal Episodes", <i>J. Am. Col. Cardiol.</i> , 33(7): 1833-1840, 1999. |
| | Avolio, A.P., "Multi-Branched Model of the Human Arterial System", <i>Med. & Biol. Eng. & Comput.</i> , 18: 709-718, 1980. |
| | Bai, et al., "A Simulation Study of External Counterpulsation", <i>Comput. Biol. Med.</i> , 24(2): 145-156, 1994. |
| | Bai, et al., "Cardiovascular Responses to External Counterpulsation: A Computer Simulation", <i>Med. Biol. Eng. Comput.</i> 30: 317-323, 1992. |
| | Berger, et al., "Arterial Wave Propagation Phenomena, Ventricular Work, and Power Dissipation", <i>Ann. Biomed. Eng.</i> 23: 804-811, 1995. |
| | Berger, et al., "Differential Effects of Wave Reflections and Peripheral Resistance on Aortic Blood Pressure: A Model-Based Study", <i>Am. J. Physiol.</i> 266: 35: H1626-H1642, 1994. |
| | Davies, "Mechanisms Involved in Endothelial Responses to Hemodynamic Forces", <i>Atherosclerosis</i> , 131: S15-S17, 1997. |
| | Diamond, et al., "Tissue Plasminogen Activator Messenger RNA Levels Increase in Cultured Human Endothelial Cells Exposed to Laminar Shear Stress" <i>Journal of Cell Physiology</i> , 143: 364-371, 1990. |
| | Holenstein, et al., "A Viscoelastic Model for Use in Predicting Arterial Pulse Waves", <i>J. Biomech. Eng.</i> 102: 318-324, 1980. |
| | Hseih, et al., "Shear Stress Increases Endothelial Platelet-Derived Growth Factor mRNA Levels" <i>American Journal of Physiology</i> , 260: H642-H646, 1991. |
| | Ichioka, et al., "Effects of Shear Stress on Wound-Healing Angiogenesis in the Rabbit Ear Chamber", <i>Journal of Surgical Research</i> , 72: 29-35, 1997. |
| | Kamiya, et al., "Adaptive Regulation of Wall Shear Stress Optimizing Vascular Tree Function", <i>Bull. Math. Biol.</i> 46: 127-137, 1984. |
| | Kamm, et al., "Unsteady Flow in a Collapsible Tube Subjected to External Pressure or Body Forces", <i>J. Fluid Mech.</i> , 95(1): 1-78, 1979. |
| | Lawson, et al., "Improved Exercise Tolerance Following Enhanced External Counterpulsation: Cardiac or Peripheral Effect?", <i>Cardiology</i> , 87(4): 271-275, 1996. |
| | Lawson, et al., "Efficacy of Enhanced External Counterpulsation in the Treatment of Angina Pectoris", <i>American Journal of Cardiology</i> , 70(9): 859-862, 1992. |
| | Lueptow, et al., "Circulatory Model Studies of External Cardiac Assist by Counterpulsation," <i>Cardiovascular Research</i> , 15(8): 443-455, 1981. |
| | Malek, et al., "Fluid Shear Stress Differentially Modulates Expression of Genes Encoding Basic Fibroblast Growth Factor and Platelet-Derived Growth Factor B Chain in Vascular |

| | | | | |
|---|--|--|---|---|
| Form PTO-1449 (REV. 8-83) | | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket: 0492611-0375 | In re Application No. 09/815,528 |
| INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i> | | Applicant: Kamrn, et al. | | |
| | | Filing Date: March 23, 2001 | Group: | |
| <p>Endothelium" <i>Journal of Clinical Investigation</i>, 92: 2013-2021, 1993.</p> <p>Mason, "The Ins and Outs of Fibroblast Growth Factors" <i>Cell</i>, 78(4): 547-552, 1994.</p> <p>Mitsumata, et al., "Fluid Shear Stress Stimulates Platelet-Derived Growth Factor Expression in Endothelial Cells" <i>American Journal of Physiology</i>, 265(1): H3-H8, 1993.</p> <p>Parmley, et al., "Hemodynamic Effects of Noninvasive Systolic Unloading (Nitroprusside) and Diastolic Augmentation (External Counterpulsation) in Patients with Acute Myocardial Infarction", <i>Am. J. Cardiol.</i> 33: 819-825, 1974.</p> <p>Pedley, et al., "Energy Losses and Pressure Drop in Models of Human Airways", <i>Respiration Physiology</i>, 9:371-386, 1970.</p> <p>Soran, et al., "Enhanced External Counterpulsation in the Management of Patients with Cardiovascular Disease", <i>Clin. Cardiol.</i> 22: 173-178, 1999.</p> <p>Soroff, et al., "External Counterpulsation, Management of Cardiogenic Shock After Myocardial Infarction", <i>J. Am. Med. Assn.</i> 229: 1441-1450, 1974.</p> <p>Stettler, et al., "Theoretical Analysis of Arterial Hemodynamics Including the Influence of Bifurcations" <i>Annals of Biomedical Engineering</i>, 9: 145-164, 1981.</p> <p>Suga, et al., "Instantaneous Pressure-Volume Relationships and Their Ratio in the Excised, Supported Canine Left Ventricle", <i>Circulation Research</i>, 35: 1974.</p> <p>Suga, et al., "Determinants of Instantaneous Pressure in Canine Left Ventricle: Time and Volume Specification", <i>Circ. Res.</i> 46: 256-263, 1980.</p> <p>Sumpio, "Hemodynamic Forces and the Biology of the Endothelium: Signal Transduction Pathways in Endothelial Cells Subjected to Physical Forces in Vitro" <i>Journal of Vascular Surgery</i>, 13(5): 744-746, 1991.</p> <p>Suresh, et al., "Maximizing the Hemodynamic Benefit of Enhanced External Counterpulsation", <i>Clinical Cardiology</i>, 21(9): 649-653, 1998.</p> <p>Young, et al., "Flow Characteristics in Models of Arterial Stenoses". <i>J. Biomechanics</i>, 6: 547-559, 1973.</p> <p>Zheng, et al., Sequential External Counterpulsation (SECP) in China", <i>Transactions of the American Society of Artificial Internal Organs</i>, 29: 599-603, 1983.</p> | | | | |